Immunology Sponsored by Beckman Coulter
Most antibody responses to SARS-CoV-2 are strong and long-lasting
How long does the immune response last in patients with the SARS-CoV-2 virus? This has been a key question in shaping the public health response to the COVID-19 pandemic, and a new report published in Science on October 28 offers some good news.  Discuss
New COVID-19 immunogen could help with early diagnosis
A new assay that detects the unique SARS-CoV-2 orf8 protein in the sera of COVID-19 patients in the early stage of the infection is a strategic step in controlling the COVID-19 pandemic, according to research published online October 20 in mBio.  Discuss
Can SARS-CoV antibodies be used to develop universal coronavirus vaccines?
Can antibodies developed against SARS-CoV during the 2003 outbreak be used to prevent infection by SARS-CoV-2? In an October 9 study published in Science Advances, researchers analyzed precious serum collected from convalescent SARS-CoV patients to find out.  Discuss
Long-lasting IgG antibodies found in blood and saliva of COVID-19 patients
Researchers have discovered that immunoglobulin G (IgG) antibodies to the SARS-CoV-2 virus are longer lasting in the blood and saliva of COVID-19 patients compared to the relatively short-lived IgM and IgA responses. The finding, presented in a pair of studies published in Science Immunology on October 8, suggests that IgG antibodies could be a promising target to detect and evaluate immune responses to the virus.  Discuss
Passive vaccines with mAbs may be effective for COVID-19
Monoclonal antibodies (mAbs) isolated from the blood of recovered COVID-19 patients -- known colloquially as "convalescent plasma" -- could be potentially useful as therapeutic and prophylactic agents for passive vaccination, assuming their administration does not trigger unwanted side effects. The findings of the new study were published in Cell on September 26.  Discuss
Are T cells more important than antibodies in COVID-19?
A new study stressed the importance of a multilayered, virus-specific immune response for controlling SARS-CoV-2 during acute COVID-19, with an emphasis on the critical nature of T cells over antibodies during the process. The work was published in Cell on September 16.  Discuss
Antibody fragments may be exceptionally effective against SARS-CoV-2
An engineered antibody fragment has been developed as a highly potent neutralizer of SARS-CoV-2. For the first time, one of these tiny molecules has been tested for efficacy in in vitro and in vivo infection models. The results of the collaborative study were published in Cell on September 14.  Discuss
Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with its deep cell characterization capabilities. These efforts are highlighted by the rapid impact that Berkeley Lights' Beacon systems had during the early days of the COVID-19 pandemic.  Discuss
New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that block inhibitory cytokines in tumor microenvironments, allowing the body to effectively eliminate tumors. The results of the study were published in Nature Communications on September 11.  Discuss
Early trials show potential of Pfizer COVID-19 vaccine
Pharmaceutical giant Pfizer is making progress on BNT162b1, a COVID-19 vaccine candidate that is undergoing development and for which the U.S. government has secured access to 300 million doses in 2021. The results of the phase I/II clinical trials were published in Nature on August 12.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter